Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1

Απλή σελίδα τεκμηρίου
dc.contributor.authorKaravasilis, V.en
dc.contributor.authorMalamou-Mitsi, V.en
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorTsanou, E.en
dc.contributor.authorKitsou, E.en
dc.contributor.authorKalofonos, H.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorFotsis, T.en
dc.contributor.authorPavlidis, N.en
dc.date.accessioned2015-11-24T19:36:15Z
dc.date.available2015-11-24T19:36:15Z
dc.identifier.issn1471-2407-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23840
dc.rightsDefault Licence-
dc.subjectAdenocarcinoma/blood supply/chemistry/pathologyen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAntigens, CD34/*analysisen
dc.subjectBrain Neoplasms/blood supply/*chemistry/pathology/secondary/therapyen
dc.subjectCarcinoma/blood supply/chemistry/pathologyen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectNeoplasms, Unknown Primary/blood supply/*chemistry/pathology/therapyen
dc.subjectNeovascularization, Pathologicen
dc.subjectThrombospondin 1/*analysisen
dc.subjectTumor Markers, Biological/*analysisen
dc.subjectVascular Endothelial Growth Factor A/*analysisen
dc.titleAngiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1en
heal.abstractBACKGROUND: Cancer of unknown primary remains a mallignancy of elusive biology and grim prognosis that lacks effective therapeutic options. We investigated angiogenesis in cancer of unknown primary to expand our knowledge on the biology of these tumors and identify potential therapeutic targets. METHODS: Paraffin embedded archival material from 81 patients diagnosed with CUP was used. Tumor histology was adenocarcinoma (77%), undifferentiated carcinoma (18%) and squamous cell carcinoma (5%). The tissue expression of CD34, VEGF and TSP-1 was assessed immunohistochemically by use of specific monoclonal antibodies and was analyzed against clinicopathological data. RESULTS: VEGF expression was detected in all cases and was strong in 83%. Stromal expression of TSP-1 was seen in 80% of cases and was strong in 20%. The expression of both proteins was not associated with any clinical or pathological parameters. Tumor MVD was higher in tumors classified as unfavorable compared to more favorable and was positively associated with VEGF and negatively with TSP-1. CONCLUSION: Angiogenesis is very active and expression of VEGF is almost universal in cancers of unknown primary. These findings support the clinical investigation of VEGF targeted therapy in this clinical setting.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1186/1471-2407-5-25-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/15743540-
heal.identifier.secondaryhttp://www.biomedcentral.com/1471-2407/5/25-
heal.journalNameBMC Canceren
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2005-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Πρωτότυπος φάκελος/πακέτο

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
Briasoulis-2005-angiogenesis in cancer.pdf
Μέγεθος:
806.08 KB
Μορφότυπο:
Adobe Portable Document Format
Κατεβάστε

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ